Cel­gene scores an­oth­er win for megablock­buster con­tender ozan­i­mod, but it's haunt­ed by key dis­abil­i­ty miss

Cel­gene post­ed an­oth­er key Phase III suc­cess for its megablock­buster con­tender ozan­i­mod, once again un­der­scor­ing its po­ten­tial to dis­rupt the mul­ti­ple scle­ro­sis field.

In­ves­ti­ga­tors held back the da­ta, but ozan­i­mod beat Avonex in re­duc­ing the an­nu­al­ized rate of re­laps­ing and re­mit­ting MS. And that will be added to the ear­li­er promis­ing Phase III re­sults be­ing pack­aged for an FDA ap­pli­ca­tion lat­er in the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER